BeiGene, Ltd. (ONC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BeiGene, Ltd. (ONC) has a cash flow conversion efficiency ratio of 0.042x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($201.94 Million) by net assets ($4.76 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ONC net asset quality score to measure how much of total assets are equity-financed.
BeiGene, Ltd. - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how BeiGene, Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BeiGene, Ltd. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
BeiGene, Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeiGene, Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alcon AG
SW:ALC
|
0.030x |
|
Telefonaktiebolaget LM Ericsson (publ)
F:ERCA
|
0.077x |
|
STMicroelectronics NV ADR
NYSE:STM
|
0.029x |
|
Baidu Inc
MX:BIDUN
|
0.009x |
|
Orsted A/S
CO:ORSTED
|
0.074x |
|
Prudential plc
F:PRU2
|
0.030x |
|
Cheniere Energy Partners LP
NYSE:CQP
|
11.667x |
|
Iron Mountain Incorporated
NYSE:IRM
|
-0.440x |
Annual Cash Flow Conversion Efficiency for BeiGene, Ltd. (2013–2025)
The table below shows the annual cash flow conversion efficiency of BeiGene, Ltd. from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see BeiGene, Ltd. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.36 Billion | $1.13 Billion | 0.259x | +712.63% |
| 2024-12-31 | $3.33 Billion | $-140.63 Million | -0.042x | +87.10% |
| 2023-12-31 | $3.54 Billion | $-1.16 Billion | -0.327x | +4.17% |
| 2022-12-31 | $4.38 Billion | $-1.50 Billion | -0.341x | -61.22% |
| 2021-12-31 | $6.13 Billion | $-1.30 Billion | -0.212x | +36.16% |
| 2020-12-31 | $3.87 Billion | $-1.28 Billion | -0.332x | +56.75% |
| 2019-12-31 | $978.36 Million | $-750.27 Million | -0.767x | -145.53% |
| 2018-12-31 | $1.75 Billion | $-547.72 Million | -0.312x | -1775.86% |
| 2017-12-31 | $684.23 Million | $12.75 Million | 0.019x | +107.35% |
| 2016-12-31 | $352.91 Million | $-89.51 Million | -0.254x | +52.69% |
| 2015-12-31 | $74.32 Million | $-39.84 Million | -0.536x | -58.90% |
| 2014-12-31 | $25.77 Million | $-8.69 Million | -0.337x | -206.16% |
| 2013-12-31 | $-36.96 Million | $4.07 Million | -0.110x | -- |
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more